Why I think Indivior plc is a growth stock for shrewd investors

You shouldn’t count out Indivior plc (LSE: INDV) just yet.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

On Friday, shares in Indivior (LSE: INDV) crashed by as much as 40% after the company announced that a US court ruling could clear the way for a generic rival to its treatment for opioid addiction that generates 80% of its revenues.

Covering the development on Friday, my Foolish colleague Peter Stephens concluded that investors should avoid the company following the ruling as its future is now “highly uncertain.” However, I believe that shares in Indivior remain attractive after this recent development. 

Building a moat

The District Court of Delaware ruled that a generic competitor to the treatment, Indian-based Dr Reddy’s, does not infringe on Indivior’s patents, clearing the way for a wave of generic competition to take on the company and the US drug market. And while this threat is substantial and very real, Indivior’s existing presence and relationship with its US customers should not be underestimated (as well as providing the pill, it provides patient management as well). 

Management has known about the possible generic threat for some time, and it has taken steps to ensure that the corporation’s business is well defended against any new entrants. Indivior has developed new products, reinforced relationships with distributors and bulked up its marketing team to help maintain market share. 

As well as working on its defences, it will benefit from wider market themes. Specifically, the US is currently in the midst of an opioid epidemic as thousands have become addicted to prescription painkillers. Policy makers are starting to wake up to this epidemic sweeping the country and are looking to take action. Indivior will benefit from any sustained drive by the government to reduce addiction levels. 

Back down to earth 

Shares in the drugmaker crashed on Friday because before the warning, the market was expecting a lot from the firm — the shares were trading at a forward P/E of 14.7. Today, the valuation has returned to a more attractive 9.7 times forward earnings. This depressed multiple reflects the depressed sentiment towards the company but also leaves plenty of room for surprises if the generic hit isn’t as bad as the market expects. 

Shire (LSE: SHP) has also fallen out of favour with investors recently too. Once again, this is another situation where investors have become worried about Shire’s growth potential as generic competitors grab market share. 

Market leader 

As the company has established itself as one of the world’s leading rare disease treatment businesses over the past few years, with numerous new products in the pipeline, I believe the majority of these concerns are unfounded, and over the long term, Shire will continue to churn out returns for investors. 

On this basis, right now the shares look to be severely undervalued compared to the drug-maker’s experience and potential. Shares in Shire trade at a forward P/E of 10.2, falling to 9.2 for 2018. For some comparison, the wider pharma sector trades at a median P/E of 17.4, so it looks as if the shares are undervalued by around 70%. 

City analysts have pencilled in earnings per share growth of 10% for 2018 so even compared to the company’s modest growth rate, shares in Shire look undervalued. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended Shire. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Would a stock market crash matter?

Christopher Ruane explains why a stock market crash could turn out to be positive, not negative, for a private investor…

Read more »

Investing Articles

Has the Rolls-Royce share price peaked?

After a strong 2023 performance and (so far) in 2024, the Rolls-Royce share price has stuttered in recent days. Christopher…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Turning a £20k ISA into a £13,900 yearly second income? It’s possible!

By investing a £20k ISA now using certain basic principles, our writer thinks he could set up a second income…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

With no savings, I’d follow Warren Buffett’s number one rule to build wealth

Can this one piece of Warren Buffett wisdom really help our writer as he aims to build wealth in the…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

A second income of £1k a month from just £10 a day! How would I do that?

Mark David Hartley considers how to build a second income stream starting from just £10 a day. Is £1,000 a…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Turn £8,900 into a £24k annual passive income? Here’s how!

Christopher Ruane applies some investing lessons from billionaire Warren Buffett when explaining how he'd aim to earn sizeable passive income…

Read more »

Young Caucasian woman holding up four fingers
Investing Articles

7%+ dividend yields! 4 FTSE 100 shares for investors to consider buying in April

These FTSE shares offer dividend yields comfortably above the index average of 3.7%. Here's why they could be good passive…

Read more »

Dividend Shares

£10k in an ISA? Here’s how to generate a ton of passive income

Passive income can provide a lot more financial freedom and security. Here’s an easy way to generate some within an…

Read more »